Webinar: The Future of Prostate Cancer is Here
August 29, 2014 |
Did you know that…
Prostate cancer is the most common non-skin cancer among men in the U.S.
A non-smoking man is more likely to develop prostate cancer than he is to develop colon, bladder, melanoma, lymphoma, and kidney cancers combined
When the cancer has spread, the 5-year survival rate drops to 28%
Provenge® (sipuleucel-T) was the first active immunotherapy to be approved by the FDA in 2010
September is Prostate Cancer Awareness Month
Charles Drake, M.D., Ph.D.
Immunotherapy: The Future of Prostate Cancer is Here
September 30, 2014, at 2:00 p.m. EDT
In immunotherapy, prostate cancer has been at the vanguard. It was the first indication for which an active systemic immunotherapy was granted approval by the FDA, in 2010. But in the past year, the checkpoint inhibitor ipilimumab (Yervoy®) failed in phase III trials—something that nobody was expecting. So what should you know?
Get the updates on prostate cancer at our webinar, Immunotherapy: The Future of Prostate Cancer is Here, on September 30, 2014, at 2:00 p.m. EDT, hosted by Charles Drake, M.D., Ph.D., an associate professor at Johns Hopkins University. Geared for patients and caregivers, Dr. Drake will go over immunotherapy, what is available right now, and what clinical trials are for you. Anything he hasn't covered, you can ask in our Q&A session.
This 45-minute online webinar, which is part of the Cancer Research Institute's Breakthroughs in Cancer Immunotherapy webinar series, is free, but registration is required. So sign up today!